School of Medicine


Showing 41-60 of 95 Results

  • Hassan Jahanandish

    Hassan Jahanandish

    Postdoctoral Scholar, Urology

    BioDr. Hassan Jahanandish is a Postdoctoral Fellow at Stanford School of Medicine, where his research focuses on the intersection of multimodal AI and medical imaging with the overarching objective of advancing care paradigms for cancer patients. Before joining Stanford, he completed his PhD in Bioengineering at the University of Texas at Dallas and the University of Texas Southwestern Medical Center (2022). Beyond his research pursuits, Hassan is an Instructor and Team Mentor at Stanford Center for Biodesign, where he helps shape the future of medical innovation and healthcare entrepreneurship. Hassan's scholarly contributions have been published in numerous journals and conferences, including Lancet Oncology, NeurIPS, and ICRA, and his work in collaboration with Nokia Bell Labs has been awarded a United States patent. Hassan's achievements have been recognized by awards such as the Jonsson Family Graduate Fellowship in Bioengineering, the Doctoral Dissertation Research Award, and being an International RehabWeek paper award finalist (2019).

  • Robert Kessler

    Robert Kessler

    Professor (Clinical) of Urology, Emeritus

    Current Research and Scholarly InterestsMale infertility; impotence; urinary calculi; urinary, incontinence (male and female)

  • Marvin Langston

    Marvin Langston

    Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology

    BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.

    Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.

    His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.

    Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work.

  • John Leppert

    John Leppert

    Professor of Urology and, by courtesy, of Nephrology

    Current Research and Scholarly InterestsOur research aims to improve the global quality of care for patients with Urologic Cancer with a particular focus on kidney cancer. We are investigating novel proteomic platforms and assays to diagnose kidney cancer and predict response to therapy. We are evaluating the comparative effectiveness of various kidney cancer surgeries and their impact on chronic kidney disease and its downstream effects. We are applying epidemiology, bioinformatics, and health services methods to urologic conditions.

  • Joseph C. Liao

    Joseph C. Liao

    Kathryn Simmons Stamey Professor

    Current Research and Scholarly InterestsThe overarching theme of my scholarship is to develop precision diagnostics in imaging and biomarkers to guide the delivery of precision therapy for urological diseases including bladder cancer, urinary tract infections, and kidney stone disease.

  • Daniel Massana Roquero

    Daniel Massana Roquero

    Postdoctoral Scholar, Urology

    BioDaniel Massana Roquero is a postdoctoral scholar who earned his PhD in Chemistry from Clarkson University (NY, USA) on development and application of smart hydrogel for biomedical applications. This work contributed to shaping his current research in the department of Urology at Stanford University, where his efforts are focused on improving kidney stone surgery outcomes.

  • Rustin Massoudi, MD

    Rustin Massoudi, MD

    Clinical Assistant Professor, Urology

    BioDr. Massoudi is a board certified urologist specializing in general urology and urologic oncology. He is a clinical assistant professor of urology at Stanford University School of Medicine. Dr. Massoudi has expertise in treating prostate cancer, kidney cancer, kidney stones, and enlarged prostate. He also cares for patients with bladder cancer, testicular cancer, urinary retention, and a wide range of other urologic conditions.

    His experience encompasses the complete spectrum of treatment options. This includes advanced, minimally invasive techniques like endoscopy and laparoscopy, as well as robotic surgery, which can enable smaller incisions and potentially shorter recovery times. For cases where a minimally invasive approach isn’t feasible, he performs open surgery.

    Dr. Massoudi partners with each patient and family to customize a treatment plan that fits their needs. He welcomes patients at all stages in their journey—from early to more advanced symptoms—and is dedicated to helping them manage their urologic health long-term. He values the rewards of helping patients through difficult times as they cope with urologic disorders.

    Dr. Massoudi was drawn to urology for its unique combination of medical and surgical care, including the opportunity to use the most innovative techniques and technology. He enjoys establishing a rapport and staying in close communication with referring physicians. To ensure all of his patients receive comprehensive care, he collaborates with Stanford colleagues from endocrinology, nephrology, medical oncology, radiation oncology, and other specialties.

    Building on his passion for biological sciences and bioengineering, Dr. Massoudi’s studies have included translational research into the use of proteomics to target proteins on the metabolic pathway of kidney cancer development. In partnership with the Stanford Kidney Cancer Research Program, he has also explored the role of the molecule IQGAP in kidney cancer cell migration, proliferation, differentiation, polarity, and adhesion.

    While working at the Veterans Administration in Palo Alto, Dr. Massoudi collaborated on an investigation into the utility of nuclear imaging methods for identifying and staging bladder cancer. He also collaborated on research that used novel proteomic technology to understand the signaling mechanisms of renal cell carcinoma; he later performed in vitro experiments on novel biomarkers and therapeutic agents for treating it.

    Dr. Massoudi has authored numerous articles on renal disorders, innovative treatment techniques and technologies, and related topics. His work has been featured in Cell, the Journal of Endourology, European Urology Oncology, Canadian Journal of Urology, American Journal of Medical Genetics, and others. He has made presentations at conferences including the American Urological Association, Society of Urology Oncology, and World Congress of Endourology.

    Dr. Massoudi has received multiple honors for teaching, scholarship, and research including a Stanford Urology Teaching Award for Outstanding
    Mentorship of Co-Residents. In addition, he won a Gold Humanism and Excellence in Teaching Award from Stanford University School of Medicine.
    At the 43rd Annual Northern California Urological Society Conference, he won top honors for his presentation on IQGAP.

  • Ashu Mohammad

    Ashu Mohammad

    Postdoctoral Scholar, Urology

    BioRecieved his PhD in molecular biology from Shoolini University, India. He is trying to understand the implications of oxidative stress and circadian rhythms in IC/BPS and Nocturia repectively.